Increased chemokine signaling in a model of HIV1-associated peripheral neuropathy.
Painful distal sensory polyneuropathy (DSP) is the most common neurological complication of HIV1 infection. Although infection with the virus itself is associated with an incidence of DSP, patients are more likely to become symptomatic following initiation of nucleoside reverse transcriptase inhibitor (NRTI) treatment. The chemokines monocyte chemoattractant protein-1 (MCP1/CCL2) and stromal derived factor-1 (SDF1/CXCL12) and their respective receptors, CCR2 and CXCR4, have been implicated in HIV1 related neuropathic pain mechanisms including NRTI treatment in rodents. Utilizing a rodent model that incorporates the viral coat protein, gp120, and the NRTI, 2'3'-dideoxycytidine (ddC), we examined the degree to which chemokine receptor signaling via CCR2 and CXCR4 potentially influences the resultant chronic hypernociceptive behavior. We observed that following unilateral gp120 sciatic nerve administration, rats developed profound tactile hypernociception in the hindpaw ipsilateral to gp120 treatment. Behavioral changes were also present in the hindpaw contralateral to the injury, albeit delayed and less robust. Using immunohistochemical studies, we demonstrated that MCP1 and CCR2 were upregulated by primary sensory neurons in lumbar ganglia by post-operative day (POD) 14. The functional nature of these observations was confirmed using calcium imaging in acutely dissociated lumbar dorsal root ganglion (DRG) derived from gp120 injured rats at POD 14. Tactile hypernociception in gp120 treated animals was reversed following treatment with a CCR2 receptor antagonist at POD 14. Some groups of animals were subjected to gp120 sciatic nerve injury in combination with an injection of ddC at POD 14. This injury paradigm produced pronounced bilateral tactile hypernociception from POD 14-48. More importantly, functional MCP1/CCR2 and SDF1/CXCR4 signaling was present in sensory neurons. In contrast to gp120 treatment alone, the hypernociceptive behavior associated with the injury plus drug combination was only effectively reversed using the CXCR4 antagonist AMD3100. These studies indicate that the functional upregulation of CCR2 and CXCR4 signaling systems following a combination of gp120 and an NRTI are likely to be of central importance to associated DSP and may serve as potential therapeutic targets for treatment of this syndrome.
Bhangoo
Sonia K
SK
Molecular Pharmacology, Northwestern University, Chicago, IL, USA. bhangoos@nidcr.nih.gov
Ripsch
Matthew S
MS
Buchanan
David J
DJ
Miller
Richard J
RJ
White
Fletcher A
FA
D000818:Animals; D002478:Cells, Cultured; D018932:Chemokine CCL2 / Q000378:metabolism; D018925:Chemokines / Q000378:metabolism*; D004195:Disease Models, Animal; D005260:Female; D005727:Ganglia, Spinal / Q000166:cytology; D015699:HIV Envelope Protein gp120 / Q000627:therapeutic use; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D010523:Peripheral Nervous System Diseases / Q000209:etiology / Q000378:metabolism* / Q000473:pathology; D051381:Rats; D019718:Receptors, CXCR4 / Q000378:metabolism; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D015398:Signal Transduction / Q000502:physiology*
D018932:Chemokine CCL2; D018925:Chemokines; D015699:HIV Envelope Protein gp120; D019718:Receptors, CXCR4; D018894:Reverse Transcriptase Inhibitors
Brain Behav Immun. 2007 Jul;21(5):581-91
17292584
Exp Neurol. 2008 Mar;210(1):30-40
18177640
J Neurochem. 2008 Jan;104(1):254-63
17944871
J Neurosci. 2006 Oct 4;26(40):10299-304
17021185
Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9075-80
19451647
Virology. 2000 Oct 25;276(2):229-37
11040114
Pain. 2006 Jun;122(3):245-257
16530964
Proc Natl Acad Sci U S A. 2002 May 14;99(10):7090-5
11983855
Eur J Neurosci. 2005 Oct;22(8):1977-86
16262636
Brain. 2006 May;129(Pt 5):1330-8
16537566
Pain. 2004 Jan;107(1-2):147-58
14715401
J Neurosci. 2002 Sep 1;22(17):7586-95
12196582
Nat Rev Neurosci. 2003 Jun;4(6):444-55
12778117
J Biol Chem. 2007 Oct 12;282(41):30062-9
17715128
Neurosci Res. 2004 Apr;48(4):463-9
15041200
J Neurosci. 2006 Jul 5;26(27):7281-92
16822986
J Neurophysiol. 1999 Dec;82(6):3347-58
10601466
J Neurosci. 2009 Jun 24;29(25):8051-62
19553445
Ann Neurol. 2003 Sep;54(3):287-96
12953261
J Biol Chem. 2005 Mar 18;280(11):9895-903
15632118
Neuron. 2005 Sep 15;47(6):787-93
16157274
Eur J Pain. 2003;7(1):23-31
12527314
Mol Cell Neurosci. 2003 Sep;24(1):1-9
14550764
Brain Res. 2009 Jan 28;1251:103-11
19059387
Eur J Pain. 2009 Mar;13(3):263-72
18554968
Mol Cell Neurosci. 2008 Jun;38(2):259-65
18434191
Neurology. 2003 Jul 22;61(2):279; author reply 279-80
12874429
J Neurosci. 2001 Jul 15;21(14):5027-35
11438578
Pain. 2007 Dec 15;133(1-3):47-63
17433546
Cell Death Differ. 2005 Aug;12 Suppl 1:878-92
15832177
Muscle Nerve. 2001 Jan;24(1):37-46
11150964
Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20151-8
18083844
J Neurophysiol. 2006 Nov;96(5):2189-99
16775210
Nature. 1998 Jun 18;393(6686):648-59
9641677
Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14092-7
16174730
Neuroscience. 2007 Nov 9;149(3):706-14
17870246
J Pain. 2006 Oct;7(10):757-67
17018336
Curr Biol. 1997 Feb 1;7(2):112-21
9024623
Eur J Neurosci. 2000 Jun;12(6):1857-66
10886327
Mol Pain. 2007 Dec 12;3:38
18076762
Pain. 2005 Jan;113(1-2):106-12
15621370
J Neurophysiol. 1999 Dec;82(6):3359-66
10601467
J Neurosci. 2007 Nov 7;27(45):12396-406
17989304
Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4536-41
15764707
J Neuroimmune Pharmacol. 2006 Jun;1(2):138-51
18040780
J Neurosci. 2001 Apr 15;21(8):2808-19
11306633
Curr Opin Neurol. 2003 Jun;16(3):403-9
12858079
Brain Behav Immun. 2007 Jul;21(5):660-7
17204394
J Neurophysiol. 2003 Mar;89(3):1588-602
12612024
Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7947-52
12808141
J Neurosci. 2009 Apr 1;29(13):4096-108
19339605
J Neuroimmunol. 2001 May 1;116(1):29-39
11311327
Brain Res. 2000 Apr 7;861(1):105-16
10751570
J Neurophysiol. 2000 Nov;84(5):2365-79
11067979
Pain. 2007 Nov;132 Suppl 1:S13-S21
17959310